AstraZeneca and Daiichi push Enhertu into earlier breast cancer use
UK-based pharma major AstraZeneca (LSE: AZN) and its Japanese partner Daiichi Sankyo (TYO: 4568) are moving to expand the reach of their blockbuster antibody-drug conjugate Enhertu (trastuzumab deruxtecan) into early-stage breast cancer, building on momentum from a recent Phase III trial in the metastatic setting.
In new results announced Wednesday, the companies said Enhertu followed by a standard chemo mix - known as THP - delivered a “statistically-significant and clinically-meaningful” improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breast cancer.
The trial, dubbed Destiny-Breast11, marks the first time Enhertu has shown a benefit in early-stage disease, potentially setting the stage for use in patients who may still be cured. The current standard in this setting is a more intensive combination involving anthracyclines, a class of chemotherapy drugs often linked to heart damage.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze